Evox Therapeutics
Oxford, United Kingdom
Hybrid — also manufactures internal programs
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
56.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (2)
○ EMA GMP
○ MHRA GMP
Quick Facts: Evox Therapeutics
- Signal Score
- 56.5/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Oxford, United Kingdom
- Modalities
- Exosome
- Active Programs
- No ClinicalTrials.gov matches confirmed — 2 partnership signals in press (announcements, not verified)
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Evox Therapeutics
Hybrid developer + CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 2 partnership announcements found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesExosome
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
53.0
1 manufacturing site: Oxford, UK
Modalities: Exosome
Capacity assessment: 53.0/100
Sites: Oxford, UK
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals2 articles (not scored)
1 manufacturing site: Oxford, UK
Modalities: Exosome
Capacity assessment: 53.0/100
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data. This company's careers site asks automated readers not to collect it (robots.txt), and we respect that.
Source:
public careers pages
· Checked Nov 20, 2026
Company Signals 2 articles
Company announcements, not verified evidence. They do not change any score.
Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit® Technology to Enable Gene Editing in Rett Syndrome - BioSpace
Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit® Technology to Enable Gene Editing in Rett Syndrome BioSpace
Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit - Business Wire
Evox Therapeutics Partners with Rett Syndrome Research Trust to Evaluate ExoEdit Business Wire
Frequently Asked Questions About Evox Therapeutics
What is Evox Therapeutics's CDMO Signal Score?
Evox Therapeutics has a Signal Score of 56/100, based on quality, operations, financial stability, and capacity data.
Evaluating Evox Therapeutics for a manufacturing program?
Use the free AI matchmaker to compare Evox Therapeutics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Esco Aster
Singapore, Singapore
Signal Score: 63.0
Cell Therapy, Exosome
Codiak BioSciences (Sarepta)
Cambridge, MA
Signal Score: 60.3
Exosome
ExoXpert (EXO Biologics)
Liège, Belgium
Signal Score: 56.5
Exosome
Exopharm
Melbourne, Australia
Signal Score: 56.5
Exosome
Clara Biotech
Indianapolis, IN
Signal Score: 56.5
Exosome
Compare Evox Therapeutics with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.